JP2020517263A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517263A5
JP2020517263A5 JP2019556956A JP2019556956A JP2020517263A5 JP 2020517263 A5 JP2020517263 A5 JP 2020517263A5 JP 2019556956 A JP2019556956 A JP 2019556956A JP 2019556956 A JP2019556956 A JP 2019556956A JP 2020517263 A5 JP2020517263 A5 JP 2020517263A5
Authority
JP
Japan
Prior art keywords
receptor
antigen
cell
protein
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019556956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517263A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/028427 external-priority patent/WO2018195348A1/en
Publication of JP2020517263A publication Critical patent/JP2020517263A/ja
Publication of JP2020517263A5 publication Critical patent/JP2020517263A5/ja
Pending legal-status Critical Current

Links

JP2019556956A 2017-04-19 2018-04-19 がんを治療するための組成物及び方法 Pending JP2020517263A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762487358P 2017-04-19 2017-04-19
US62/487,358 2017-04-19
PCT/US2018/028427 WO2018195348A1 (en) 2017-04-19 2018-04-19 Compositions and methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2020517263A JP2020517263A (ja) 2020-06-18
JP2020517263A5 true JP2020517263A5 (https=) 2020-07-30

Family

ID=63856183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556956A Pending JP2020517263A (ja) 2017-04-19 2018-04-19 がんを治療するための組成物及び方法

Country Status (6)

Country Link
US (1) US20210095029A1 (https=)
EP (1) EP3612222A4 (https=)
JP (1) JP2020517263A (https=)
CN (1) CN110536700A (https=)
AU (1) AU2018254517A1 (https=)
WO (1) WO2018195348A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020118094A1 (en) * 2018-12-06 2020-06-11 Guangdong Tcrcure Biopharma Technology Co., Ltd. Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
WO2020180591A1 (en) 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Dll3 targeting chimeric antigen receptors and binding agents
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
CA3146019A1 (en) 2019-07-17 2021-01-21 Nanjing Legend Biotech Co., Ltd. Anti-dll3 chimeric antigen receptors and uses thereof
WO2021155518A1 (en) * 2020-02-05 2021-08-12 Tcrcure Biopharma Corp Anti-hpv t cell receptors and engineered cells
EP4168451A2 (en) 2020-06-22 2023-04-26 NGM Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
CN111704675B (zh) * 2020-07-08 2022-05-10 武汉波睿达生物科技有限公司 一种治疗hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
CN114437229B (zh) * 2020-11-01 2024-03-12 复旦大学 携带pd-1単链抗体且靶向egfr抗原的car t免疫细胞的制备及其用途
CN116134139B (zh) * 2021-09-09 2026-04-14 菲鹏弘济生物(深圳)有限公司 一种转基因免疫效应细胞及其应用
CN115025217B (zh) * 2022-05-13 2023-05-05 广东齐美医药生物科技集团有限公司 干细胞裂解物联合活性多糖以及酪氨酸酶抑制剂在制备药物或化妆品中的用途
CN119286780B (zh) * 2024-12-12 2025-03-21 山东省成体细胞产业技术研究院有限公司 一种t细胞的体外培养方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2961831T (pt) * 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
US11161907B2 (en) * 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (en) * 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
HK1254803A1 (zh) * 2015-06-23 2019-07-26 Memorial Sloan Kettering Cancer Center 新型pd -1的免疫调节剂
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
CN105796597A (zh) * 2016-03-11 2016-07-27 江苏三特生物科技有限公司 携带pd-l1和ctla-4抗体基因的car-t细胞在肿瘤免疫上的应用
US11549099B2 (en) * 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CN107523547A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抑制性抗体的car‑t细胞及其用途

Similar Documents

Publication Publication Date Title
JP2020517263A5 (https=)
JP2025037871A5 (https=)
JP2021500861A5 (https=)
IL273201B1 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
IL321733A (en) Compositions and methods for selective degradation of proteins
JP2020500530A5 (https=)
JP2021525509A5 (https=)
JPWO2019232503A5 (https=)
JPWO2021188599A5 (https=)
RU2018122106A (ru) Буферы для стабилизации лентивирусных препаратов
HRP20230457T1 (hr) Pripravci i postupci za selektivnu ekspresiju kimernih antigenskih receptora
JP2017504601A5 (https=)
JP2024059628A (ja) Cd19指向性キメラ抗原受容体および免疫療法におけるその使用
JP2019518424A5 (https=)
FI3380620T3 (fi) Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
US20210095029A1 (en) Compositions and methods for treating cancer
US20230028399A1 (en) Bcma-directed cellular immunotherapy compositions and methods
JP2019525956A5 (https=)
IL297514A (en) Vectors and methods for in vivo transduction
IL297547A (en) Therapeutic interventional particles for the corona virus
CN113307872B (zh) 一种工程化核酸、t细胞及其应用和产生方法
CN117222421A (zh) T细胞调节多肽和其使用方法
JPWO2021041806A5 (https=)
CN117070454A (zh) 一种car-t细胞的制备方法
JP2019531742A5 (https=)